Date: 2026-06-21
Format: APA | Mode: all
Results: 7 validated, 1 suggestions, 0 errors out of 8 total
| # | Code | Similarity | Reference |
|---|---|---|---|
| 1 | OK | 100% |
ORIGINAL:
Packer, M., Zile, M. R., & Kramer, C. M. (2025). Tirzepatide for heart failure with preserved ejection fraction and obesity. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2410027
FORMATTED (APA):
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., & Borlaug, B. A. (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 392(5), 427-437. https://doi.org/10.1056/nejmoa2410027 |
| 2 | SUGGESTION | 70% |
ORIGINAL:
Packer, M.(2025). Tirzepatide for heart failure with preserved ejection fraction and obesity. New England Journal of Medicine.
FORMATTED (APA):
Packer, M. (2025). What Causes Inflammation in Heart Failure With a Preserved Ejection Fraction?. JACC: Heart Failure, 13(12), 102638. https://doi.org/10.1016/j.jchf.2025.102638 |
| 3 | OK | 100% |
ORIGINAL:
Borlaug, B. A., Jensen, M. D., & Kitzman, D. W. (2023). Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovascular Research. https://doi.org/10.1093/cvr/cvac120
FORMATTED (APA):
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023). Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovascular Research, 118(18), 3434-3450. https://doi.org/10.1093/cvr/cvac120 |
| 4 | OK | 100% |
ORIGINAL:
Packer, M., Lam, C. S., & Lund, L. H. (2020). Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.1902
FORMATTED (APA):
Packer, M., Lam, C. S., Lund, L. H., Maurer, M. S., & Borlaug, B. A. (2020). Characterization of the Inflammatory-Metabolic Phenotype of Heart Failure with a Preserved Ejection Fraction: A Hypothesis to Explain Influence of Sex on the Evolution and Potential Treatment of the Disease. European Journal of Heart Failure, 22(9), 1551-1567. https://doi.org/10.1002/ejhf.1902 |
| 5 | OK | 100% |
ORIGINAL:
Kosiborod, M. N., Abildstrøm, S. Z., & Borlaug, B. A. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2306963
FORMATTED (APA):
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., ... Petrie, M. C. (2023). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 389(12), 1069-1084. https://doi.org/10.1056/nejmoa2306963 |
| 6 | OK | 100% |
ORIGINAL:
Kosiborod, M. N., Petrie, M. C., & Borlaug, B. A. (2024). Semaglutide in patients with obesity-related heart failure and type 2 diabetes. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2313917
FORMATTED (APA):
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., Jensen, T. J., Liisberg, K., Lindegaard, M. L., Abhayaratna, W., Ahmed, F. Z., Ben-Gal, T., Chopra, V., Ezekowitz, J. A., Fu, M., ... Shah, S. J. (2024). Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. New England Journal of Medicine, 390(15), 1394-1407. https://doi.org/10.1056/nejmoa2313917 |
| 7 | OK | 100% |
ORIGINAL:
Willard, F. S., Douros, J. D., & Gabe, M. B. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. https://doi.org/10.1172/jci.insight.140532
FORMATTED (APA):
Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J., Stutsman, C., Cardona, G. R., Urva, S., Emmerson, P. J., Holst, J. J., D’Alessio, D. A., Coghlan, M. P., Rosenkilde, M. M., Campbell, J. E., & Sloop, K. W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17), e140532. https://doi.org/10.1172/jci.insight.140532 |
| 8 | OK | 100% |
ORIGINAL:
Reddy, Y. N. V., Carter, R. E., & Sundaram, V. (2024). An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score. Nature Medicine. https://doi.org/10.1038/s41591-024-03140-1
FORMATTED (APA):
Reddy, Y. N. V., Carter, R. E., Sundaram, V., Kaye, D. M., Handoko, M. L., Tedford, R. J., Andersen, M. J., Sharma, K., Obokata, M., Verbrugge, F. H., & Borlaug, B. A. (2024). An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score. Nature Medicine, 30(8), 2258-2264. https://doi.org/10.1038/s41591-024-03140-1 |
Want to verify your own citations?
Try Citation Verification Tool